drugset / Trial / NCT03878303
Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
Phase 1
Unknown
32 enrolled
ACEA Therapeutics, Inc.
Hangzhou ACEA Pharmaceutical Research Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 1b, double blind, randomized, placebo-controlled study of the safety and tolerability, pharmacokinetics and pharmacodynamics of AC0058TA in patients with systemic lupus erythematosus (SLE).
Timeline
- Start
- 2018-11-28
- Primary completion
- 2020-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AC0058TA | Small molecule | 50 mg | Oral |
| Subject | AC0058TA | Small molecule | 100 mg | Oral |
| Subject | AC0058TA | Small molecule | 200 mg | Oral |